BTMD
biote Corp.NASDAQHealthcare$1.59+11.19%ClosedMarket Cap: $70.1M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
2.59
PEG
0.00
P/B
-0.86
P/S
0.38
EV/EBITDA
4.03
DCF Value
$5.28
FCF Yield
41.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.5%
Operating Margin
18.5%
Net Margin
14.1%
ROE
-35.3%
ROA
25.1%
ROIC
43.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $46.4M | $2.0M | $0.06 |
| FY 2025 | $192.2M | $27.0M | $0.74 |
| Q3 2025 | $48.0M | $8.2M | $0.22 |
| Q2 2025 | $48.9M | $3.2M | $0.10 |
Analyst Ratings
View AllB. Riley SecuritiesNeutral
2026-03-12TD CowenBuy
2026-03-12B. Riley SecuritiesNeutral
2025-08-07Trading Activity
Insider Trades
View AllChristensen Bretdirector, officer: Chief Executive Officer
SellFri Apr 03
Peterson Robert Charlesofficer: Chief Financial Officer
SellFri Apr 03
Barrera Richard Rdirector, 10 percent owner:
SellWed Jun 11
MORRIS DEBRA Ldirector
SellThu May 15
MORRIS DEBRA Ldirector
SellThu May 15
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.29
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.